GlassScriptPhysician profile
Sara Parnell
NPI 1669032850
$2,937.18
in general payments reported to CMS, 2019-2025
20 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $679 · 2022: $1,080 · 2023: $907 · 2024: $140 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,178.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $543.46 | 2021-2023 | Perseris, Sublocade |
| Abbvie INC. | $468.71 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $461.55 | 2022-2025 | Caplyta |
| Lundbeck LLC | $250.12 | 2021-2023 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $225.84 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $208.26 | 2021-2024 | Spravato |
| Teva Pharmaceuticals USA, INC. | $183.56 | 2021-2023 | Austedo Xr, Austedo |
| Sunovion Pharmaceuticals INC. | $172.76 | 2021-2022 | |
| Alkermes, INC. | $162.99 | 2021-2023 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $39.48 | 2021-2022 | |
| Gilead Sciences, INC. | $31.51 | 2021 | |
| Vanda Pharmaceuticals INC. | $28.79 | 2022 | |
| Neurocrine Biosciences, INC. | $26.58 | 2022 | |
| Avanir Pharmaceuticals, INC. | $21.97 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $21.35 | 2024 | Airsupra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $20.81 | 2021 | |
| Corium, LLC | $19.57 | 2022-2025 | Azstarys |
| Oxford Immunotec USA INC | $18.54 | 2021 | |
| Axsome Therapeutics, INC. | $15.70 | 2025 | Auvelity |
| Lilly USA, LLC | $15.63 | 2025 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Parnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.